Roles of E-Cadherin (CDH1) Genetic Variations in Cancer Risk: a Meta-analysis

Abstract

E-Cadherin (CDH1) genetic variations may be involved in invasion and metastasis of various cancers byaltering gene transcriptional activity of epithelial cells. However, published studies on the association of CDH1gene polymorphisms and cancer risk remain contradictory, owing to differences in living habits and geneticbackgrounds. To derive a more better and comprehensive conclusion, the present meta-analysis was performedincluding 57 eligible studies of the association between polymorphisms of CDH1 gene promoter -160 C>A, -347G>GA and 3’-UTR +54 C>T and cancer risk. Results showed that these three polymorphisms of CDH1 weresignificantly associated with cancer risk. For -160 C>A polymorphism, -160A allele carriers (CA and CA+AA)had an increased risk of cancer compared with the homozygotes (CC), and the similar result was discoveredfor the -160A allele in the overall analyses. In the subgroup analyses, obvious elevated risk was found with-160A allele carriers (AA, CA, CA+AA and A allele) for prostate cancer, while a decreased colorectal cancerrisk was shown with the AA genotype. For the -347 G>GA polymorphism, the GAGA genotype was associatedwith increased cancer risk in the overall analysis with homozygous and recessive models. In addition, results ofsubgroup analysis indicated that the elevated risks were observed in colorectal cancer and Asian descendants.For +54 C>T polymorphism, a decreased risk of cancer was found in heterozygous, dominant and allele models.Moreover, +54T allele carriers (CT, CT+TT genotype and T allele) showed a potential protective factor in gastriccancer and Asian descendants.